Atypical hemolytic uremic syndrome
Other Names for this Disease
- Atypical HUS
- HUS, atypical
- GeneReviews provides current, expert-authored, peer-reviewed, full-text articles describing the application of genetic testing to the diagnosis, management, and genetic counseling of patients with specific inherited conditions. Click on the link to view the article on this topic.
The Rare Thrombotic Diseases Consortium aims to improve the lives of people with antiphospholipid antibody syndromes, heparin-induced thrombocytopenia, paroxysmal nocturnal hemoglobinuria, catastrophic antiphospholipid antibody syndrome (thrombotic storm), and thrombotic thrombocytopenic purpura (TTP) through research.
For more information, please contact:
Hemostasis and Thrombosis Research Center
Duke University Health System
P.O. Box 3422 DUMC
315 Trent Dr. Rm 273
Durham, NC 27710
Medical ProductsThe medication(s) listed in the table(s) below have been approved by the Food and Drug Administration (FDA) for treatment of this condition. The FDA Office of Orphan Products Development designates "orphan products" for those that treat rare diseases affecting fewer than 200,000 Americans. The table(s) below may not be an exhaustive list of drugs or products used to treat this condition. There may be other products available that are not considered orphan products. To search for all FDA approved drugs, visit Drugs@FDA. You can find orphan products used to treat other conditions by searching the Orphan Drug Product Designation database.
(Alexion Pharmaceuticals, Inc.)
The FDA has approved this product to be used in this manner.
|For the treatment of atypical Hemolytic Uremic Syndrome (aHUS)|
|More Information about this product||
Drug Information Portal
Medline Plus Health Information